Clearmind Medicine Inc., a pioneering biotech company devoted to uncovering and developing novel psychedelic-derived therapeutics, proudly announced today that Professor Joseph Tam, D.M.D., Ph.D., presented the latest results of their pre-clinical trial for the drug candidate MEAI, a potential treatment for obesity, at Isranalytica 2023. This groundbreaking development could revolutionize the way we treat this prevalent yet under-treated health issue.
Clearmind recently presented exciting data on its drug candidate, 5-Methoxy-2-aminoindane (MEAI), at a presentation titled “The Psychoactive Drug 5-Methoxy-2-aminoindane (MEAI) Ameliorates Obesity and its Metabolic Complications.” Pre-clinical results showed that MEAI has the potential to treat obesity and metabolic syndrome, providing a promising new treatment option for those suffering from these conditions.
At Isranalytica 2023, the Annual Meeting of the Israel Analytical Chemical Society, attendees will have the opportunity to witness the research of Professor Joseph Tam, D.M.D., Ph.D., and his team from the Obesity and Metabolism Laboratory at the Hebrew University’s Institute for Drug Research. Under the guidance of Dr. Saja Baraghithy, Ph.D., Professor Tam and his team have conducted a pre-clinical trial as part of Clearmind’s collaboration with the Hebrew University and its technology transfer company Yissum, that promises to leave a lasting impression in the world of analytical chemistry.
Clearmind’s CEO Dr. Adi Zuloff-Shani expressed his pride in the promising results of their MEAI-based treatment for obesity. Professor Joseph Tam presented these findings to medical professionals and fellow scientists, which was a crucial step in increasing awareness of this unique treatment among the scientific and medical community and furthering the development of future clinical programs.
About Clearmind Medicine Inc.
Clearmind is a revolutionary psychedelic pharmaceutical biotech company that is determined to tackle widespread and underserved health problems like alcohol use disorder. Through its cutting-edge research and development, the company is aiming to make novel psychedelic-derived therapeutics a reality, and to provide effective, safe, and regulated medicines, foods or supplements that can help people in need.
The company is committed to developing its intellectual portfolio, currently consisting of seven patent families, and actively seeks out new patents to enhance their portfolio. They remain ever vigilant in their efforts to acquire additional intellectual property, ensuring they remain at the cutting edge of innovation.
Clearmind’s stock is traded on three major exchanges: Nasdaq, the Canadian Securities Exchange, and the Frankfurt Stock Exchange. You can find its stock symbol, CMND, on Nasdaq and CWY on the Frankfurt Stock Exchange. With its presence on three different exchanges, Clearmind is positioning itself to make a big splash in the world of finance.
At Yissum, we strive to build a better tomorrow. Founded in 1964, we are the technology transfer company of The Hebrew University of Jerusalem, transforming cutting-edge academic research into commercial solutions that address our world’s most pressing challenges. With over 11,000 patents registered around the world, over 1,140 licensed technologies, and more than 200 spin-off companies, Yissum has become a global bridge between academia and industry, working with partners such as Boston Scientific, ICL, Intel, Johnson & Johnson, Merck and Novartis. We are dedicated to leveraging extraordinary innovations and transformational technologies to benefit society.